Viropro Inc.

VPRO

US9282422057

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:30:00 2024-04-11 am EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2016	Viropro Inc. Announces Resignation of Kenneth Sorensen as Board of Director	CI
2016	Viropro Seeks Acquisitions	CI

Viropro Inc. Announces Resignation of Deborah O'Shea as General Counsel and Chief Operating Officer

September 23, 2013 at 10:02 am EDT

On September 15, 2013, Deborah O'Shea, General Counsel and Chief Operating Officer (COO) of Viropro, resigned.

Latest news about Viropro Inc.

Viropro Inc. Announces Resignation of Kenneth Sorensen as Board of Director	16-09-27	CI
Viropro Seeks Acquisitions	16-05-04	CI
Viropro Inc. Announces Executive Changes	16-05-02	CI
Viropro Inc. cancelled the acquisition of NovaRx Corporation.	16-05-01	CI
Viropro Inc. Announces Board Changes	16-04-25	CI
Viropro Inc. Announces the Resignation of John Doll from Board of Directors	16-04-21	CI
Viropro, Inc. Announces Appointment of John Doll to Board of Directors	16-02-11	CI
Viropro Inc. Announces Executive Changes	16-01-22	CI
Viropro, Inc. Names Ivor Royston to its Board of Directors	15-12-08	CI
Viropro Inc. signed a Letter of Intent to acquire NovaRx Corporation	15-10-21	CI
Viropro Announces Plan for Restructuring	15-02-02	CI
Viropro Inc. announced that it has received $0.2 million in funding from SpringHill Bioventures Sdn Bhd.	14-08-24	CI
Viropro Inc. Announces Executive Changes	14-06-02	CI
Viropro Inc. cancelled the acquisition of Therapix Biosciences Ltd. from a group of investors.	14-05-03	CI
Viropro Inc. signed a non-binding letter of intent to acquire Therapix Biosciences Ltd. from a group of investors.	13-12-03	CI
Viropro Inc. Announces Resignation of Deborah O'Shea as General Counsel and Chief Operating Officer	13-09-23	CI
Viropro Inc. and Oncobiologics, Inc. Sign Emerging Markets Biosimilars Deal	13-02-25	CI
Viropro Inc. Announces Board Changes	12-10-19	CI
Viropro Inc. Announces Resignation of Rajiv Datar as President and CEO	12-08-15	CI
Viropro Inc. announced that it has received $0.03 million in funding from Magna Equities II, LLC.	12-03-20	CI

Viropro, Inc. is engaged in the development and manufacturing of biopharmaceutical drugs. The Company conducts operations primarily through its subsidiary, Alpha Biologics Sdn Bhd (Alpha) located in Penang, Malaysia. The Company intends to offer solution to the biopharma industry from drug concept through to product manufacturing. The Alpha facility consists of approximately 50,000 square feet of research and production space. The Alpha facility is designed to support the scale-up and manufacture of monoclonal antibodies.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VIROPRO INC.	0.00%	1.27K
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+2.01%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.58%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs

Viropro Inc.

Equities

VPRO

US9282422057

Biotechnology & Medical Research

Viropro Inc. Announces Resignation of Deborah O'Shea as General Counsel and Chief Operating Officer

Latest news about Viropro Inc.

Chart Viropro Inc.

Company Profile

Sector Bio Therapeutic Drugs